Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

Researchers Define Long-Term Outcomes of Cancer-Associated Thrombosis

Patients diagnosed with cancer-associated thrombosis (CAT) remain at a high risk for recurrent venous thromboembolism (VTE), bleeding, and death – even while on therapeutic...

Romiplostim Helps Patients With Glioblastoma and Thrombocytopenia Stay on Treatment

Temozolomide (TMZ) is part of the standard treatment for patients with glioblastoma, but the drug carries a dosedependent risk of grade 3 or 4...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...

Tagraxofusp: A New Option for Blastic Plasmacytoid Dendritic Cell Neoplasm?

Treatment with tagraxofusp, an anti-CD123 targeted agent previously known as SL-401, appeared to be safe and effective for managing blastic plasmacytoid dendritic cell neoplasm...

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European Hematology Association, the four-drug regimen of nivolumab plus doxorubicin,...

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated a relationship between B-type natriuretic peptide (BNP) and N-terminal...

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.